OxyLo
Enabling scientists to easily and affordably mimic the oxygen levels of the body in a dish.
At a glance
-
Development stage
Active / generating revenue
-
Investment stage
Pre-Seed
-
UNSW affiliation
Spinout - staff led
-
Technology readiness level
TRL-4
OxyLo develops novel research tools that control oxygen in a dish to aid biologists with fundamental and preclinical research.
Competitors use expensive CapEx equipment while OxyLo can achieve microscale level control at the cost of a research kit. OxyLo currently has over 17 beta testers worldwide.
-
OxyLo’s patent-pending HypoxyCaps are microscale beads with enzymes that locally remove oxygen. By adding different amounts in a cell culture dish, scientists can directly control the level of oxygen for the cells, better mimicking healthy and diseased tissues for studies and drug screening.
OxyLo’s kits can be sold by common science distributors (e.g., Sigma, Fischer) for USD600 as a lab consumable, bypassing the need for CapEx grant funds.
-
- Oxygen level is critical for many aspects of biology: modelling cancer hypoxia, liver zonation, stem cell differentiation, etc.
- Current oxygen controlling technology costs >AUD20K.
- These machines can only set one oxygen level at a time.
- The incubators and gas equipment take up significant lab space.
-
- University research scientists who study fundamental biology
- Preclinical researchers at biotech companies who want to improve their drug screening models
-
- 17 beta users
- One manuscript from a collaborator who successfully used the HypoxyCaps
- A pending NIH SBIR grant for USD1.3 million
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.